secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024461
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences Q3 revenue $18.7M (+43% YoY); narrows FY22 guidance to $70-72M
-----------------------------------------------------------------------------

- Surgical Glaucoma revenue $17.1M (+37% YoY); Dry Eye revenue $1.6M (+145% YoY).
- Net loss $22.2M ($0.46 per share) vs. $17.2M ($0.43) in Q3 2021.
- Gross margin 84%; operating expenses $37.6M (+50% YoY).
- Full-year 2022 revenue guidance tightened to $70-72M from prior $68-72M.
- Launched SION bladeless goniotomy device; completed enrollment for SAHARA dry eye trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000095017022024461/0000950170-22-024461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000095017022024461/sght-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer